Caris Life Sciences, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CAI in the last 7 days.
No SEC Form 4 filings for $CAI in the last 30 days.
See all $CAI insider activity →CA Immobilien Anlagen AG (CAI) agreed to sell its Czech platform. The deal is pending customary conditions and is expected to close soon. The sale is part of the company's portfolio repositioning, according to the press release.
JP Morgan maintained an Overweight rating for Caris Life Sciences Inc (CAI) and raised its price target to $35 from $25, citing confidence in the company's future performance. CAI's P/E ratio is 81.33x, higher than its 5-year median, and its GF Score™ is 11/100, indicating areas for improvement. Insider activity shows significant selling. CAI specializes in molecular science and technology, focusing on precision medicine in oncology.
Denton John Russel (See Remarks) sold 7,500 shares of Caris Life Sciences, Inc. (CAI) at $31.82 ($0.24M total) on 2026-09-22.
Recent CAI coverage spans insider activity, corporate actions and earnings.
The divestiture may modestly improve balance sheet and focus, but no financial details were disclosed.
Analyst price target increase suggests potential upside for CAI.
Small insider sale likely has minimal price impact.
Potential sector-level upside optionality if FDA approval supports broader category acceptance.
Large insider sale may signal negative sentiment and put downward pressure on CAI stock.
AlphAI scores every news story that mentions CAI with an AI model for sentiment and relevance, and aggregates insider trades from Caris Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CA Immobilien Anlagen AG (CAI) agreed to sell its Czech platform. The deal is pending customary conditions and is expected to close soon. The sale is part of the company's portfolio repositioning, according to the press release.
1 min readJP Morgan maintained an Overweight rating for Caris Life Sciences Inc (CAI) and raised its price target to $35 from $25, citing confidence in the company's future performance. CAI's P/E ratio is 81.33x, higher than its 5-year median, and its GF Score™ is 11/100, indicating areas for improvement. Insider activity shows significant selling. CAI specializes in molecular science and technology, focusing on precision medicine in oncology.
2 min readDenton John Russel (See Remarks) sold 7,500 shares of Caris Life Sciences, Inc. (CAI) at $31.82 ($0.24M total) on 2026-09-22.
1 min readGrail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.
6 min readBrille Brian J (See Remarks) sold 400,000 shares of Caris Life Sciences, Inc. (CAI) at $30.33 ($12.13M total) on 2026-09-17.
1 min readCaris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure Beginning on September 14, 2026, representatives of Caris Life Sciences, Inc. (the “ Company ”) intend to use an investor presentation (the “ Investor Presentation ”) in meetings with current and potential investors at the Morgan Stanley 24th An
1 min readSpetzler David Baxley (President) sold 597,212 shares of Caris Life Sciences, Inc. (CAI) at an average of $24.84 ($24.76–$25.32, $14.83M total) across 3 trades over 2026-09-03 to 2026-09-04.
1 min readCaris Life Sciences (NASDAQ: CAI) published a study in npj Precision Oncology on an AI tool for pancreatic cancer treatment. The tool, part of the Caris Molecular Tumor Board Report, predicts patient outcomes for two treatments, with median survival of 16 months for FOLFIRINOX vs. 9.9 months for gemcitabine plus nab-paclitaxel. The company's MI Cancer Seek test, FDA-approved in November 2024, includes this tool.
2 min readCaris Life Sciences (CAI) stock rose 73% from its May low, closing at $24.58 on August 20. The rally followed record revenue of $263.71 million and raised full-year guidance. Analysts' target prices range from $25 to $36, with a mid-target of ~$25. Management highlighted potential margin expansion due to cost reductions and pricing gains, but the stock trades at 86x forward earnings, indicating high valuation.
2 min readJourney Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
3 min read
